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Coronavirus is a single-stranded RNA type of viruses, 
and in humans, this causes respiratory diseases 
varying from the common cold to severe/fatal 
illnesses1. There are three types of coronaviruses 
which infected the human, associated with deadly 
phenomena. Starting with severe acute respiratory 
syndrome coronavirus (SARS-CoV), Middle-East 
respiratory syndrome coronavirus (MERS-CoV), and 
now Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2)2,3. 
The first case of SARS-CoV-2 was found in China, and 
it has killed millions of people worldwide from 
November 2020 to February 2021. The World Health 
Organization (WHO) announced Coronavirus disease 
(COVID-19) as the pandemic in 20204,5. The SARS-
CoV-2 threat was spread in China and other countries 
rapidly. Thus, many efforts have been run to 
investigate suitable preventive and control strategies 
for COVID-19. Various available antiviral and 
antimicrobial drugs were used to treat human SARS-
CoV-2, which are also used for treating previous 
Ebola, Zika, Nipah, MERS-CoVs, and SARS viruses6. 
These antivirals are preferred because new drug and 
vaccine development requires more than 5 to 20 years. 
Therefore, researchers focused on available 
therapeutics, which have proven efficacy against 
viruses similar to COVID-197. These agents being used 
against SARS-CoV-2 treatment could be either virus-
based, target viral S protein, some viral protease 
inhibitors, and some are receptor-binding domain–
angiotensin-converting enzyme 2 (RBD–ACE2) 
blockers or host cell-based including host cell protease 
inhibitors and host cell endocytosis inhibitors8,9. 
The spike proteins of SARS-CoV-2 carry S1 receptor 
binding subunit and S2 fusion subunit, and it directly 
arbitrates for viral entry with S1 site, which is essential 
for binding of host cell surface by ACE2. The binding 
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SARS-CoV-2, a new type of Coronavirus, has affected more millions 
of people worldwide. From the spread of this infection, many studies 
related to this virus and drug designing for the treatment have been 
started. Most of the studies target the SARS-CoV-2 main protease, 
spike protein of SASR-CoV-2, and some are targeting the human furin 
protease. In the current work, we chose the clinically used drug 
molecules remdesivir, favipiravir, lopinavir, hydroxychloroquine, and 
chloroquine onto the target protein SARS-CoV-2 main 
protease. Docking studies were performed using ArgusLab, while 
Discovery Studio collected 2D and 3D pose views with the crystal 
structure of COVID-19 main protease in complex with an inhibitor N3 
with PDB ID 6LU7. Computational studies reveal that all ligands 
provided good binding affinities towards the target protein. Among 
all the chosen drugs, lopinavir showed the highest docking score of -
11.75 kcal/mol. The results from this molecular docking study 
encourage the use of lopinavir as the first-line treatment drug due to 
its highest binding affinity. 
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of the virus with the host cell surface is followed by 
S1/S2 cleave through host protease as TMPRSS2, 
cathepsins B and L10. Studies on these particular drugs 
are currently undergoing tests for their efficacy and 
safety in treating COVID-19 worldwide. Despite the 
possible side effects, some positive and encouraging 
results have been achieved so far11-15. 
In the present study, we have investigated the binding 
of five active molecules, currently applied as the first-
line treatment, favipiravir, hydroxychloroquine, 
remdesivir, lopinavir, and ritonavir, on one of the 
possible target proteins, RBD of SARS-CoV-2 main 
protease (MPro) by molecular docking simulations. The 
selected drug, like remdesivir, is an antiviral prodrug 
of C-adenosine nucleoside analog GS-44152416,17. It is 
metabolized in cells into active nucleoside 
triphosphate derivative, which intervenes in the 
activity of RNA-dependent RNA polymerase (RdRp) 
and further leads to the termination of viral RNA18. 
Lopinavir is an antiviral drug, which inhibits viral 
protease. It was first approved in 2000 for the 
treatment of HIV infection. It is used in combination 
with ritonavir, which shows a synergistic effect 
improving its antiviral activity19. Favipiravir (6-fluoro-
3-hydroxy-2-pyrazinecarboxamide) is an antiviral 
prodrug that was first used to treat influenza in Japan. 
It is also used to treat avian influenza (H5N1 influenza 
virus), Ebola, Lassa, Rabies, Bunyavirus, West Nile, 
and yellow fever viruses20. Chloroquine and its 
derivative hydroxychloroquine were developed for 
the treatment of malaria. Chloroquine, along with its 
derivative hydroxychloroquine, is also used to treat 
HIV and rheumatoid arthritis. Chloroquine passively 
diffuses through the cell membrane into cell organelles 
like lysosomes and endosomes, where it is protonated, 
leading to an increase in the endosomal pH. This 
results in the abrogation of the virus-receptor binding 
and cell entry21,22. From this background, through this 
research, we aim to elucidate target selection for future 
drug design studies for COVID-19. 
 
METHOD 
Hardware and Software 
The software used was CORINA Classic from 
Molecular Networks GmbH and Altamira, LLC 
(https://www.mn-am.com/products/corina), 
ArgusLab 4.0.1 from Mark Thompson and Planaria 
Software LLC 
(http://www.arguslab.com/arguslab.com/ArgusLa
b.html), and Discovery Studio Visualizer v20.1.0.19295 





The compounds included in the study were 
remdesivir (PubChem ID 121304016), favipiravir 
(492405), lopinavir (92727), hydroxychloroquine 
(3652), and chloroquine (2719), which downloaded 
from the PubChem database 
(https://pubchem.ncbi.nlm.nih.gov/). 
Receptors 
Docking simulations were performed with the X-ray 
structure of the crystal structure of SARS-CoV-2 MPro 
in complex with an inhibitor N3 (PDB ID 6LU7)23, 
which downloaded from Protein Data Bank 
(https://www.rcsb.org). 
Docking protocol 
Preparation of ligands 
The ligand structures were generated using the tool 
CORINA Classic. Three-dimensional optimizations of 
the ligand structures were done and saved as .mol file. 
Geometry optimizations of the ligands were 
performed according to the Hartree–Fock (HF) 
calculation method using ArgusLab 4.0.124. 
Preparation of protein 
The protein sequence was retrieved in the FASTA 
format, and the 3D structure was determined using the 
CPH model server. All water molecules were 
removed, and hydrogen atoms were added to the 
target protein molecule. 
Protein-ligand docking 
ArgusLab was an electronic structure program that 
was based on quantum mechanics. It predicts the 
potential energies, molecular structures, geometry 
optimization of the structure, vibration frequencies of 
coordinates of atoms, bond length, and bond angle25. 
The selected bioactive antivirals were docked using 
ArgusLab Software. The interaction was carried out to 
find the favorable binding geometries of the ligand 
with the protein. Docking of the protein-ligand 
complex was mainly targeted only to the predicted 
active site. Docking simulations were performed by 
selecting “ArgusDock” as the docking engine. The 
selected residues of the receptor were defined to be a 
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part of the binding site. A spacing of 0.4 Å between the 
grid points was used, and an exhaustive search was 
performed by enabling the “High precision” option in 
the Docking precision menu, “Dock” was chosen as 
the calculation type, “flexible” for the ligand, and the 
“AScore” was used as the scoring function. A 
maximum of 150 poses was allowed to be analyzed; 
the binding site box size was 20 × 20 × 20 Å to 
encompass the entire active site. The A Score function, 
with the parameters read from the AScore.prm file, 
was used to calculate the binding energies of the 
resulting docked structures. All the ligands in the 
dataset were docked into the protein’s active site using 
the same protocol. The docking poses saved for each 
compound were ranked according to their docking 
score function. The pose having the highest docking 
score was selected for further analysis26. Discovery 
Studio Visualizer was used for the visualization of 2D 
and 3D pose views. 
 
RESULTS AND DISCUSSION 
The affinity of ligands was presented by docking score 
(binding energy in kcal/mol), in which the more 
negative the value reflects the better binding affinity. 
All five ligands were docked against the target 
proteins, in which the nitrogen and oxygen atoms of 
the selected ligand were available for the hydrogen 
bond formation with the different amino acids of the 
target protein. When the docking of taken ligands was 
performed on the selected protein, the docking score 
for the ligands showed good binding affinity, as 
presented in Table I. 
Notably, lopinavir has the best binding affinity than 
other ligands with the selected protein with the lowest 
free energy of binding (ΔG) of -11.75 kcal/mol. 
Meanwhile, the ligand with the highest ΔG was 
favipiravir with -5.81 kcal/mol. Study of docking also 
suggested that amino acid residues His-246, Leu-253, 
Ile-152, Phe-8, Thr-292, Gln-110, and Asn-151 were the 
common residues, which participated in the different 
bond formation like hydrogen bond, Van der Waals 
bond, Pi-anion interaction, and these amino acid 
residues play a key role for bond formation with the 
selected protein target as shown in Figures 1 to 5. 
Interactions on these amino acids have a distance of 
less than 3.0 Å, so the interactions that occur are worth 
considering. 




Interacting atoms, amino 
acid residues, and the 
distance (Å) 
Lopinavir -11.75 1731-N; 110-Gln; 2.19 Å 
1730-O; 110-Gln; 2.94 Å 
1731-N; 110-Gln; 2.71 Å 
Remdesivir -8.83 2345-O; 153-Asp; 2.79 Å 
1731-N; 110-Gln; 2.94 Å 
Chloroquine -8.7 4552-N; 298-Arg; 2.66 Å 
2342-O; 153-Asp; 2.67 Å 
Hydroxychloroquine -8.39 2339-N; 153-Asp; 2.94 Å  
1645-O; 105-Asp; 2.51 Å 
1731-N; 110-Gln; 2.99 Å 
Favipiravir -5.81 4278-O; 280-Thr; 2.46 Å  
4273-N; 280-Thr; 2.31 Å  
3307-N; 218-Trp; 2.98 Å 






Figure 1. (A) 2D and (B) 3D poses of lopinavir in SARS-CoV-2 
MPro. 




















Figure 4. (A) 2D and (B) 3D poses of hydroxychloroquine in 
SARS-CoV-2 MPro. 






Figure 5. (A) 2D and (B) 3D poses of favipiravir in SARS-CoV-
2 MPro. 
 
The results obtained were different from those 
reported by Eweas et al.27, who reported that 
remdesivir was more potent than lopinavir. However, 
the results of this study were consistent with those 
reported by Mothay & Ramesh28, who reported better 
potency of lopinavir than remdesivir. It should be 
considered that the two studies used different 
software (Molegro Virtual Docker and AutoDock) 
than the one used in this study. The use of ArgusLab 
for docking against SARS-CoV-2 MPro was reported by 
Das et al.29, but with a different PDB (6Y84). 
Meanwhile, the docking of these ligands using 
ArgusLab with the 6LU7 receptor was first reported in 
this study, so the results of this study were expected to 




COVID-19 pandemic has been approached through 
various methods, involving newly developed vaccines 
under clinical trials. Since the in vivo and in vitro studies 
take a long time and effort, molecular docking of 
selective ligands and targets is helpful in these studies. 
Computational docking allowed us to find the binding 
affinity of the ligand with the target protein 6LU7. This 
finding shows the efficacy of the drugs in inhibiting 
the viral activity and spread of infection. In this 
comparative study, lopinavir showed the highest 
docking score of -11.75 kcal/mol, making it the most 
potent inhibitor among the other approved drugs. The 
results from this molecular docking study encourage 
the use of lopinavir as the first-line treatment drug due 
to its highest binding affinity. 
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